GW-501516 CARDARINE POWDER – 1000MG / 1 GRAM
- Additional information
GW-501516 Cardarine Information
|Purity||≥99% Pure (LC-MS)|
|Storage||Store in cool dry environment, away from direct sunlight.|
|Terms||Lab Use Only. This information is for educational purposes only and does not constitute medical advice.|
GW-501516 Cardarine studies were famously pioneered by world-class biologist Ronald Evans at the Salk Institute in La Jolla, CA.
Shipping Conditions: Ambient temperature.
**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).
 G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: A dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation. 2006.
 L. Gu, Y. Shi, W. Xu, and Y. Ji, “PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by Regulating miR-206,” Oncol. Res., vol. 27, no. 8, pp. 923–933, Aug. 2019.
 S. D. Saibil et al., “Activation of peroxisome proliferator-activated receptors a and D synergizes with inflammatory signals to enhance adoptive cell therapy,” Cancer Res., vol. 79, no. 3, pp. 445–451, Feb. 2019.
 R. W. Smith, J. D. Coleman, J. T. Thompson, and J. P. Vanden Heuvel, “Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells,” Biochem. Biophys. Reports, vol. 8, pp. 395–402, Dec. 2016.
 W. Fan et al., “PPARδ Promotes Running Endurance by Preserving Glucose,” Cell Metab., vol. 25, no. 5, pp. 1186-1193.e4, May 2017.
 V. A. Narkar et al., “AMPK and PPARδ Agonists Are Exercise Mimetics,” Cell, 2008.
 Y. X. Wang et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, 2003.
 D. L. Sprecher et al., “Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist,” Arterioscler. Thromb. Vasc. Biol., 2007.
 T. Tanaka et al., “Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proc. Natl. Acad. Sci. U. S. A., vol. 100, no. 26, pp. 15924–15929, Dec. 2003.
 U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E. O. Muscat, “The Peroxisome Proliferator-Activated Receptor β/δ Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells,” Mol. Endocrinol., vol. 17, no. 12, pp. 2477–2493, Dec. 2003.
 Z. Zhang et al., “PPARδ agonist prevents endothelial dysfunction via induction of dihydrofolate reductase gene and activation of tetrahydrobiopterin salvage pathway,” Br. J. Pharmacol., vol. 176, no. 16, pp. 2945–2961, Aug. 2019.
 W. J. Lee et al., “Activation of PPARδ attenuates neurotoxicity by inhibiting lipopolysaccharide-triggered glutamate release in BV-2 microglial cells,” J. Cell. Biochem., vol. 119, no. 7, pp. 5609–5619, Jul. 2018.
 G. D. Barish et al., “PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis,” Proc. Natl. Acad. Sci. U. S. A., vol. 105, no. 11, pp. 4271–4276, Mar. 2008.
 K. Ito et al., “A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance,” Nat. Med., 2012.
 T. Fujino et al., “Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion,” Proc. Natl. Acad. Sci. U. S. A., 2003.
 S. L. Conarello et al., “Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance,” Proc. Natl. Acad. Sci. U. S. A., 2003.
 W. R. Oliver et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proc. Natl. Acad. Sci. U. S. A., 2001.
 T. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, “The PPARδ agonist GW0742X reduces atherosclerosis in LDLR -/- mice,” Atherosclerosis, 2005.
 C. H. Lee et al., “PPARδ regulates glucose metabolism and insulin sensitivity,” Proc. Natl. Acad. Sci. U. S. A., 2006.
 R. J. Kishton, M. Sukumar, and N. P. Restifo, “Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy,” Cell Metabolism. 2017.
 U. Risérus et al., “Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, Reduces oxidative stress, and increases fatty acid oxidation in moderately obese men,” Diabetes, 2008.
 E. M. M. Ooi, G. F. Watts, D. L. Sprecher, D. C. Chan, and P. H. R. Barrett, “Mechanism of action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity,” J. Clin. Endocrinol. Metab., 2011.
Buy SARMs for sale like our GW 501516 Cardarine – 20MG/ML – 30 ML bottle from UMBRELLA Labs and enjoy the highest quality and purity GW 501516 Cardarine available online.
VIEW CERTIFICATES OF AUTHENTICITY (COA)
|Dimensions||3 × 3 × 5 in|